Type Size

    Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss

    The authors examined the function of IL-20 in osteoclastogenesis and the therapeutic potential of an anti–IL-20 monoclonal antibody 7E for treating osteoporosis.  They found that IL-20 mediated osteoclastogenesis by up-regulating the receptor activator of NF-κB (RANK) expression in osteoclast precursor cells and RANK ligand (RANKL) in osteoblasts. In addition, 7E treatment completely inhibited osteoclast differentiation induced by macrophage colony-stimulating factor (M-CSF) and RANKL in vitro and protected mice from OVX-induced bone loss in vivo.


    Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details